Defining HER2 status is crucial in the management of advanced GOC patients, as HER2 positive cases by IHC (and ISH, when required) may benefit from trastuzumab in combination with first-line chemotherapy.5,6,17 Missing HER2 positive tumours could then result in unexploited treatment opportunities, considering also that enrolment in clinical trials with novel anti-HER2 agents may be a suitable option. This evidence concerns the gene ERBB2 and neoplasm.